Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.58 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920767 | 0.81 | SIGMAR1 (0.55) | SIGMAR1DCUN1D1MCHR1 | |
| SCHEMBL1921568 | 0.79 | SIGMAR1 (0.60) | SIGMAR1DCUN1D1KMT2AALDH1A1POLB | |
| SCHEMBL1921353 | 0.78 | MCHR1 (0.59) | SIGMAR1MCHR1 | |
| SCHEMBL1920596 | 0.78 | TEAD1 (0.54) | SIGMAR1DCUN1D1KMT2AMEN1MCHR1 | |
| SCHEMBL12533621 | 0.78 | SIGMAR1 (0.63) | SIGMAR1DCUN1D1KMT2AALDH1A1KDM4E | |
| SCHEMBL1920906 | 0.77 | SCN1A (0.42) | SIGMAR1KMT2AMEN1 | |
| SCHEMBL1920778 | 0.75 | ACHE (0.58) | ALDH1A1 | |
| SCHEMBL1921477 | 0.75 | SIGMAR1 (0.57) | SIGMAR1KMT2AALDH1A1POLBMEN1 | |
| Trifluoroacetic Acid SCHEMBL1921312 | 0.75 | SIGMAR1 (0.56) | SIGMAR1DCUN1D1KMT2AALDH1A1KDM4E | |
| SCHEMBL28365128 | 0.74 | SIGMAR1 (0.60) | SIGMAR1DCUN1D1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622914-B1 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | TROVIS PHARMACEUTICALS LLC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7030240-B2 | 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | HTR5A, HTR2C, HTR1A | SIGMAR1 1187/4885DCUN1D1 1527/4885KMT2A 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.